T
38.98
0.66 (1.71%)
| Previous Close | 38.32 |
| Open | 37.89 |
| Volume | 95,456 |
| Avg. Volume (3M) | 3,987,188 |
| Market Cap | 4,239,204,608 |
| Price / Sales | 302.64 |
| Price / Book | 15.36 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -1.08 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 30.89 |
| Operating Cash Flow (TTM) | -71.66 M |
| Levered Free Cash Flow (TTM) | -44.95 M |
| Return on Assets (TTM) | -22.15% |
| Return on Equity (TTM) | -32.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Terns Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.25 |
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 100.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vivo Capital, Llc | 30 Sep 2025 | 6,895,746 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 53.95%) | Buy |
| Median | 56.00 (43.68%) | |
| Low | 15.00 (JMP Securities, -61.51%) | Buy |
| Average | 51.25 (31.50%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 38.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 11 Dec 2025 | 57.00 (46.25%) | Buy | 47.09 |
| 26 Nov 2025 | 35.00 (-10.20%) | Buy | 28.75 | |
| BMO Capital | 09 Dec 2025 | 54.00 (38.55%) | Buy | 42.57 |
| 18 Nov 2025 | 30.00 (-23.03%) | Buy | 27.56 | |
| Barclays | 09 Dec 2025 | 56.00 (43.68%) | Buy | 42.57 |
| 25 Nov 2025 | 36.00 (-7.63%) | Buy | 29.35 | |
| HC Wainwright & Co. | 09 Dec 2025 | 60.00 (53.94%) | Buy | 42.57 |
| 04 Nov 2025 | 20.00 (-48.69%) | Buy | 17.43 | |
| Mizuho | 09 Dec 2025 | 54.00 (38.55%) | Buy | 42.57 |
| 13 Nov 2025 | 33.00 (-15.33%) | Buy | 20.73 | |
| Oppenheimer | 09 Dec 2025 | 58.00 (48.81%) | Buy | 42.57 |
| Truist Securities | 09 Dec 2025 | 56.00 (43.68%) | Buy | 42.57 |
| 19 Nov 2025 | 35.00 (-10.20%) | Buy | 27.12 | |
| JMP Securities | 23 Oct 2025 | 15.00 (-61.51%) | Buy | 7.50 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |